Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL056 (recombinant human parathyroid hormone [1–34]) dosing regimens in postmenopausal osteoporosis
ChiCTR2600124671Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Xinfutai in osteoporosis (4 arms), sponsored by Peking University Third Hospital. Primary endpoints: Treatment-emergent adverse events (TEAEs) and Treatment-related adverse events (TRAEs). Planned start May 2026; status: not yet recruiting.
02
Drugs
Xinfutai
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2600124671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124671.